Phio Pharmaceuticals Files 8-K
Ticker: PHIO · Form: 8-K · Filed: Sep 3, 2025 · CIK: 1533040
| Field | Detail |
|---|---|
| Company | Phio Pharmaceuticals Corp. (PHIO) |
| Form Type | 8-K |
| Filed Date | Sep 3, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k, corporate-reporting
TL;DR
Phio Pharma filed a routine 8-K, no major news.
AI Summary
Phio Pharmaceuticals Corp. filed an 8-K on September 3, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The company, formerly known as RXi Pharmaceuticals Corp., is incorporated in Delaware and headquartered in King of Prussia, PA. This filing does not appear to contain specific financial figures or material events beyond the standard reporting requirements.
Why It Matters
This 8-K filing indicates routine corporate reporting by Phio Pharmaceuticals Corp. to the SEC, without disclosing specific new material events or financial performance details.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report and does not contain information that suggests an immediate change in the company's risk profile.
Key Players & Entities
- Phio Pharmaceuticals Corp. (company) — Registrant
- RXi Pharmaceuticals Corp. (company) — Former company name
- September 3, 2025 (date) — Date of earliest event reported
- King of Prussia, PA (location) — Principal executive offices
- Delaware (location) — State of incorporation
FAQ
What is the primary purpose of this 8-K filing for Phio Pharmaceuticals Corp.?
The primary purpose of this 8-K filing is to report "Other Events" and "Financial Statements and Exhibits" as of September 3, 2025.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on September 3, 2025.
What was Phio Pharmaceuticals Corp. formerly known as?
Phio Pharmaceuticals Corp. was formerly known as RXi Pharmaceuticals Corp.
Where are Phio Pharmaceuticals Corp.'s principal executive offices located?
Phio Pharmaceuticals Corp.'s principal executive offices are located at 411 Swedeland Road, Suite 23-1080, King of Prussia, PA 19406.
In which state is Phio Pharmaceuticals Corp. incorporated?
Phio Pharmaceuticals Corp. is incorporated in Delaware.
Filing Stats: 448 words · 2 min read · ~1 pages · Grade level 9.4 · Accepted 2025-09-03 08:08:28
Key Financial Figures
- $0.0001 — h registered: Common Stock, par value $0.0001 per share PHIO The Nasdaq Capital M
Filing Documents
- phio_8k.htm (8-K) — 29KB
- phio_ex9901.htm (EX-99.1) — 12KB
- image_001.jpg (GRAPHIC) — 3KB
- 0001683168-25-006641.txt ( ) — 210KB
- phio-20250903.xsd (EX-101.SCH) — 3KB
- phio-20250903_lab.xml (EX-101.LAB) — 33KB
- phio-20250903_pre.xml (EX-101.PRE) — 22KB
- phio_8k_htm.xml (XML) — 4KB
01. Other Events
Item 8.01. Other Events. On September 3, 2025, Phio Pharmaceuticals Corp. ("Phio") issued a press release announcing that it is a presenting company at the H.C. Wainwright 27 th Annual Global Investment Conference to be held September 8-10, 2025. Phio also announced in the press release that patients are now being treated in the 5 th cohort of its ongoing Phase 1b clinical trial for skin cancer.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Number Description 99.1 Press Release, dated September 3, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 3, 2025 PHIO PHARMACEUTICALS CORP. By: /s/ Robert J. Bitterman Name: Title: Robert J. Bitterman President & Chief Executive Officer 3